Dr Punie discusses the patient-reported outcomes (PROs) from the Phase 3 ASCENT-03 study, comparing sacituzumab govitecan (SG) to chemotherapy in treatment-naïve advanced triple-negative breast cancer (TNBC) patients not eligible for PD-(L)1 inhibitors.

The analysis demonstrated that SG was associated with significant improvements in physical and role functioning, global health status, and fatigue, with minimal impact from gastrointestinal side effects.